Open AccessHidradenitis suppurativa – biologic therapy and other available treatment options
Author(s) -
Katarzyna Lipa,
Natalia Zając,
Grzegorz Witkowski,
Piotr Ciechanowicz,
Kacper Wiszniewski,
Elżbieta Szymańska,
Irena Walecka
Publication year - 2023
Publication title -
postępy dermatologii i alergologii
Language(s) - English
Resource type - Journals
eISSN - 2299-0046
pISSN - 1642-395X
DOI - 10.5114/ada.2021.112075
Subject(s) - medicine , hidradenitis suppurativa , dermatology , intensive care medicine , pathology , disease
Hidradenitis suppurativa (HS) is a chronic recurrent inflammatory skin disease which is characterized by painful, recurrent nodules and abscesses. The overall prevalence of HS is estimated to be 11 per 100 000 individuals in the United States and 4% of the world's population. Women are three times more affected than men, especially patients between 18 and 29 years. Similarly to acne vulgaris, HS is primarily associated with follicular occlusion, which results from a number of biological processes, including follicular epithelial hyperplasia and hyperkeratinization. There are numerous available treatment options for cutaneous lesions in the course of HS. A combination of conservative therapy and appropriate surgical treatment conducted by an experienced surgeon ensures the best possible clinical outcomes. Presently, biologic therapy is the most effective pharmacological treatment in patients with a moderate-to-severe course of the disease. Numerous ongoing clinical trials provide hope for greater availability of new biologic therapy methods.